botulinum toxin neuromodulator — Competitive Intelligence Brief

botulinum toxin neuromodulator (botulinum toxin neuromodulator) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Neurology, Aesthetics, Pain Management.

phase 3 Neuromuscular blocking agent SNARE complex (synaptobrevin, SNAP-25, syntaxin) Neurology, Aesthetics, Pain Management Biologic

Target snapshot

botulinum toxin neuromodulator (botulinum toxin neuromodulator) — Galderma R&D. Botulinum toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
botulinum toxin neuromodulator TARGET	botulinum toxin neuromodulator	Galderma R&D	phase 3	Neuromuscular blocking agent	SNARE complex (synaptobrevin, SNAP-25, syntaxin)
Rocuronium	Rocuronium Bromide	Merck & Co.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Tracrium Preservative Free	Atracurium Besylate	Pfizer Inc.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptor sites on motor end-plate	1983-01-01
Rocuronium Injectable Solution	Rocuronium Injectable Solution	Federal University of São Paulo	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
injection of NMBA	injection of NMBA	Fondation Ophtalmologique Adolphe de Rothschild	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2039-07-22 — Rocuronium · 11998605 · Formulation · US

Sponsor landscape (Neuromuscular blocking agent class)

1. Galderma R&D · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
4. Allergan · 1 drug in this class
5. Seganest · 1 drug in this class
6. University of California, Los Angeles · 1 drug in this class
7. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class